ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

The Quick Take
SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress....
Ground Level News gathers headlines from public news feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire.



